title: Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.
abstract: Antisense oligonucleotide-mediated alternative splicing has great potential for treatment of Duchenne muscular dystrophy (DMD) caused by mutations within nonessential regions of the dystrophin gene. We have recently shown in the dystrophic mdx mouse that exon 23, bearing a nonsense mutation, can be skipped after intramuscular injection of a specific 2'-O-methyl phosphorothioate antisense oligoribonucleotide (2OMeAO). This skipping created a shortened, but in-frame, transcript that is translated to produce near-normal levels of dystrophin expression. This expression, in turn, led to improved muscle function. However, because DMD affects muscles body-wide, effective treatment requires dystrophin induction ideally in all muscles. Here, we show that systemic delivery of specific 2OMeAOs, together with the triblock copolymer F127, induced dystrophin expression in all skeletal muscles but not in cardiac muscle of the mdx dystrophic mice. The highest dystrophin expression was detected in diaphragm, gastrocnemius, and intercostal muscles. Large numbers of fibers with near-normal level of dystrophin were observed in focal areas. Three injections of 2OMeAOs at weekly intervals enhanced the levels of dystrophin. Dystrophin mRNA lacking the targeted exon 23 remained detectable 2 weeks after injection. No evidence of tissue damage was detected after 2OMeAO and F127 treatment either by serum analysis or histological examination of liver, kidney, lung, and muscles. The simplicity and safety of the antisense protocol provide a realistic prospect for treatment of the majority of DMD mutations. We conclude that a significant therapeutic effect may be achieved by further optimization in dose and regime of administration of antisense oligonucleotide.
authors.affiliation: Muscle Cell Biology, Medical Research Council Clinical Science Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. qi.lu@carolinashealthcare.org
authors.forename: Qi Long
authors.initials: QL
authors.lastname: Lu
authors.forename: Adam
authors.initials: A
authors.lastname: Rabinowitz
authors.forename: Yun Chao
authors.initials: YC
authors.lastname: Chen
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Yokota
authors.forename: HaiFang
authors.initials: H
authors.lastname: Yin
authors.forename: Julia
authors.initials: J
authors.lastname: Alter
authors.forename: Atif
authors.initials: A
authors.lastname: Jadoon
authors.forename: George
authors.initials: G
authors.lastname: Bou-Gharios
authors.forename: Terence
authors.initials: T
authors.lastname: Partridge
mesh_terms: D000818:Animals; D016189:Dystrophin / Q000235:genetics* / Q000378:metabolism; D005091:Exons / Q000502:physiology; D051379:Mice; D018101:Mice, Inbred mdx; D018482:Muscle, Skeletal / Q000378:metabolism*; D020388:Muscular Dystrophy, Duchenne / Q000628:therapy*; D020320:Oligoribonucleotides, Antisense / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D011095:Polyethylenes / Q000633:toxicity; D011126:Polypropylenes / Q000633:toxicity
chemical_list: D016189:Dystrophin; D020320:Oligoribonucleotides, Antisense; D011095:Polyethylenes; D011126:Polypropylenes; C078661:UCON 50-HB-5100